Amgen's Q4 and full-year earnings call revealed strong operating performance, with a diverse portfolio of products driving growth. The company expects total revenues to be between $17.8 billion and $18.2 billion in 2013, representing a 3-5% growth rate, and adjusted earnings per share to fall between $6.85 and $7.15. Management expressed confidence in the company's long-term growth potential, citing international expansion plans, biosimilars, and a strong pipeline. The stock is likely to react positively to the strong earnings and confident guidance.

[2]